



How to Order

SELECT IMPORTANT SAFETY INFORMATION

The labeling for LIFYORLI contains warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity. Serious adverse reactions ($\geq 2\%$) in patients who received LIFYORLI plus nab-paclitaxel were neutropenia, pneumonia, pleural effusion, febrile neutropenia, and fatigue. Fatal adverse reactions (2.1%) were septic shock, cardiac arrest, ischemic stroke, and intestinal perforation. The most common adverse reactions ($>20\%$), including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Please see additional Important Safety Information on pages 6-7 and the accompanying full [Prescribing Information](#).



LIFYORLI™ (relacorilant) Product Information

Brand name	LIFYORLI
Generic name	Relacorilant
Indication	LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
Dosage and administration	The recommended dosage of LIFYORLI is 150 mg orally once on the day before, the day of, and the day after each nab-paclitaxel infusion until disease progression or unacceptable toxicity. The recommended dosage for nab-paclitaxel is 80 mg/m² administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
NDCs	150 mg: 76346-550-09 (9-dose), 76346-550-03 (3-dose),* 76346-450-01 (1-dose) 125 mg: 76346-525-09 (9-dose), 76346-525-03 (3-dose),† 76346-425-01 (1-dose) See table on page 3 for additional information.
Storage and handling	Store and dispense LIFYORLI in their original carton. Store LIFYORLI at 20 °C to 25 °C (68 °F to 77 °F); excursions are permitted from 15 °C to 30 °C (59 °F to 86 °F).
How supplied	LIFYORLI capsules are supplied as 1-dose (1 day), 3-dose (1 week), or 9-dose (28-day). A 1-dose carton contains 1 blister card. A 3-dose carton contains 1 blister card with 3 doses. A 9-dose carton contains 3 cartons each with 1 blister card, with 3 doses per blister card.
Dosage form and strength	• LIFYORLI is available as soft gelatin capsules containing 25 mg or 100 mg of relacorilant, designed to be used together for the prescribed regimen • LIFYORLI 25 mg are opaque dark brown, oval soft gelatin capsules with “CR25” printed in black • LIFYORLI 100 mg are opaque yellow, oblong soft gelatin capsules with “CR100” printed in black



Visit LIFYORLIhcp.com

*NDC 76346-550-03 is a 3-dose supply carton and can be dispensed individually if needed.

†NDC 76346-525-03 is a 3-dose supply carton and can be dispensed individually if needed.
NDC, National Drug Code.

2 Please see additional Important Safety Information on pages 6-7 and the accompanying full [Prescribing Information](#).

 **Lifyorli**
(relacorilant) 100 mg, 25 mg capsules

How Supplied: LIFYORLI™ NDCs

> 150 mg

Supply	Carton	NDC number
9-dose	3 cartons (NDC 76346-550-03)* each containing one blister card with three 150 mg doses	76346-550-09
1-dose	1 blister card containing one 150 mg dose	76346-450-01

*NDC 76346-550-03 is a 3-dose supply carton and can be dispensed individually if needed.
Each 150 mg dose consists of one 100 mg capsule and two 25 mg capsules.



> 125 mg

Supply	Carton	NDC number
9-dose	3 cartons (NDC 76346-525-03)* each containing one blister card with three 125 mg doses	76346-525-09
1-dose	1 blister card containing one 125 mg dose	76346-425-01


*NDC 76346-525-03 is a 3-dose supply carton and can be dispensed individually if needed.
Each 125 mg dose consists of one 100 mg capsule and one 25 mg capsule.



Questions? Please call LIFYORLI Support at
1-85-LIFYORLI (1-855-439-6754) from 8 AM to 8 PM ET
or visit LIFYORLIhcp.com/support

How to Order

Access LIFYORLI™ through the following channels



*See contact information listed on the next page.

4 Please see additional Important Safety Information on pages 6-7 and the accompanying full [Prescribing Information](#).

 **Lifyorli**™
(relacorilant) 100 mg, 25 mg capsules

LIFYORLI™ Distributor Information

> Specialty distributors

Distributor name	Phone	Fax	Website
BioCareSD	(800) 304-3064	N/A	biocare-us.com
Cardinal Health Specialty Distribution	(855) 855-0708	(877) 274-9897	orderexpress. cardinalhealth.com
Cencora ASD Healthcare	(800) 746-6273	(800) 547-9413	asdhealthcare.com
Cencora Oncology Supply	(800) 633-7555	(800) 248-8205	oncologysupply.com
McKesson Plasma and Biologics	(877) 625-2566	(888) 752-7626	connect. mckesson.com
McKesson Specialty Health	(800) 482-6700	(800) 289-9285	mscs.mckesson.com

> Specialty pharmacy network*

Pharmacy name	Phone	Fax	Website
Onco360 (Sina Drug, LLC d/b/a Onco360 Louisville)	(877) 662-6633	(877) 662-6355	www.onco360.com

*For US and Puerto Rico.

Important Safety Information

INDICATIONS & USAGE

LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.

IMPORTANT SAFETY INFORMATION

Contraindications: LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids.

Warnings and Precautions:

Neutropenia and Severe Infections: LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections. There was one fatal event of septic shock with febrile neutropenia. Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Withhold dose, reduce dose, or permanently discontinue LIFYORLI based on severity.

Adrenal Insufficiency: LIFYORLI can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. Monitor for signs and symptoms of adrenal insufficiency. Withhold LIFYORLI and administer glucocorticoid therapy if adrenal insufficiency is suspected. After resolution of adrenal insufficiency, resume previous dose, reduce dose, or permanently discontinue LIFYORLI based on severity.

Exacerbation of Conditions Treated with Glucocorticoids: Use of LIFYORLI in patients taking systemic glucocorticoids for other conditions (e.g., autoimmune disorders) may exacerbate these conditions. LIFYORLI may make systemic glucocorticoids less effective and coadministration of systemic glucocorticoids may make LIFYORLI less effective. Monitor patients for reduced effectiveness of LIFYORLI and glucocorticoids in patients receiving both.

Embryo-Fetal Toxicity: LIFYORLI can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.

Adverse Reactions:

Serious adverse reactions ($\geq 2\%$) in patients who received LIFYORLI plus nab-paclitaxel were neutropenia, pneumonia, pleural effusion, febrile neutropenia, and fatigue. Fatal adverse reactions (2.1%) were septic shock, cardiac arrest, ischemic stroke, and intestinal perforation.

The adverse reaction ($>2\%$) that resulted in permanent discontinuation of LIFYORLI in patients was intestinal obstruction. Adverse reactions ($\geq 5\%$) that required dosage interruptions of LIFYORLI in combination with nab-paclitaxel in patients included neutropenia, anemia, and fatigue.

Adverse reactions requiring dose reductions of LIFYORLI included fatigue, decreased appetite, abdominal pain, neutropenia, edema, and sciatica.

The most common adverse reactions ($>20\%$) in patients who received LIFYORLI plus nab-paclitaxel, including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

Important Safety Information (cont)

Drug Interactions:

- **Strong CYP3A Inducers:** Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers.
- **CYP2C8 Inducers and Moderate CYP3A Inducers:** Monitor for reduced effectiveness of LIFYORLI plus nab-paclitaxel with CYP2C8 inducers and moderate CYP3A inducers.
- **CYP2C8 Inhibitors:** Monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended.
- **CYP3A Substrates:** Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates.
- **Certain CYP2C8 Substrates:** Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP2C8 substrates.

Use in Specific Populations:

- **Lactation:** Advise women not to breastfeed during treatment with LIFYORLI and for 1 week after the last dose.
- **Geriatric Use:** A higher incidence of grade 3-4 adverse events and dosage modification occurred in patients aged ≥65 years compared to younger adult patients.
- **Hepatic Impairment:** Avoid LIFYORLI in combination with nab-paclitaxel in patients with moderate or severe hepatic impairment.

Please see additional Important Safety Information on pages 6-7 and the accompanying full [Prescribing Information](#).

Reference: LIFYORLI™. Prescribing information. Corcept Therapeutics, Inc.; 2026.